Sauter Matthias, Schmid Holger, Anders Hans J, Heller Florian, Weiss Max, Sitter Thomas
Department of Nephrology, Medizinische-Poliklinik-Innenstadt, Klinikum der Universität Muenchen, Germany.
Clin Transplant. 2009 Jan-Feb;23(1):132-6. doi: 10.1111/j.1399-0012.2008.00912.x. Epub 2008 Dec 4.
The recurrence of anti-glomerular basement membrane (anti-GBM) glomerulonephritis (GN) in renal transplants is very rare. We report on a patient that developed acute renal allograft dysfunction due to anti-GBM GN relapse 18 months after transplantation. As plasmaseperation, dose escalation of MMF, steroids and cyclophosphamids did not result in an improvement of the graft function, a therapy with the anti-CD20 antibody Rituximab was established in addition to plasmaseperation, cyclophosphamid and steroids. Although this resulted in a decrease of anti-GBM antibody titer, graft function deteriorated further and a renal replacement therapy had to be initiated.
抗肾小球基底膜(anti-GBM)肾小球肾炎(GN)在肾移植中复发极为罕见。我们报告一例患者,在移植18个月后因anti-GBM GN复发出现急性肾移植功能障碍。由于血浆置换、霉酚酸酯剂量递增、类固醇和环磷酰胺治疗均未改善移植肾功能,遂在血浆置换、环磷酰胺和类固醇治疗基础上,加用抗CD20抗体利妥昔单抗治疗。尽管这使得anti-GBM抗体滴度下降,但移植肾功能进一步恶化,不得不启动肾脏替代治疗。